The nation of Zimbabwe has turned down a substantial American healthcare agreement valued at $367m (272 million pounds) spanning five years over the United States' request for confidential biological samples.
This rejection was revealed after a official document dated December was disclosed, indicating that Head of State Emmerson Mnangagwa believed the agreement was "unbalanced".
A government spokesman later clarified that the United States was requesting genetic material for research and commercial gain while was unwilling to share the benefits from future vaccines.
"We are forced to start the challenging and unfortunate process of ending our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had donated more than $1.9bn in health funding to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has called for more negotiations to reach a agreement acceptable to all parties so the nation's critical HIV programme can continue.
Wider Background
This rejection follows a similar situation in Kenya, where a court blocked a similar health funding agreement following legal challenges were filed about the safety of Kenyans' medical information.
Since returning to office recently, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
The agency had overseen aid for the US government, but Trump argued its expenditure was "wasteful" and his government was pursuing direct bilateral agreements to boost transparency and accountability.
Based on statements, 16 African countries have so far agreed to these new agreements, constituting over $18.3bn in new funding.
Specifics of the Rejected Deal
This assistance for Zimbabwe was intended to gone towards "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this cooperation could have provided immense advantages for Zimbabwean communities, particularly the 1.2 million men, women and children presently receiving antiretroviral therapy through US-supported initiatives," Tremont added.
However, government spokesperson Nick Mangwana maintained the proposed deal was "asymmetrical".
"Our nation was requested to provide its genetic material and health information for a long time, with no corresponding promise of access to any medical innovations – like new medicines or tests – that might result from that provided information," Mangwana explained.
"Put simply, our nation would provide the raw materials for medical research without any certainty that the resulting innovations would be accessible to our population should a future pandemic arise."
Sovereignty and Global Health
He also noted that the US's withdrawal from the global health body and its pursuit of bilateral deals were disrupting systems previously set up via the international organization.
Mangwana cited its Pathogen Access and Benefit Sharing framework created to manage future global health emergencies.
"This framework is designed to ensure that when a nation provides its samples, the benefits – including medicines and cures – are distributed fairly, not commercialised exclusively by those with the funds to develop them."
These objections over the US deal "must not be interpreted as opposition to America," he added.
"We are open to ongoing discussions with our US partners on how subsequent collaboration could be structured in a way that honours the independence and dignity of both nations."
Health Experts Response
Medical experts said it recognised the government's concerns, but urged that negotiations should continue considering much of the nation's Aids initiatives depended on foreign aid.
"If technical issues arise, including those relating to data governance or agreement terms, these can often be resolved via detailed discussion and negotiated safeguards," it commented.
The situation highlights the ongoing debate between receiving crucial foreign assistance and safeguarding a country's data in an increasingly interconnected world.